Dechra Pharmaceuticals, founded in 1997 following a management buy-out from Lloyds Chemists, develops prescription only veterinary medicines for dogs, cats and horses. Most of its projects involve adapting treatments, currently used by humans, for the animal market. It listed in London in 2000.


Updates from The Motley Fool

Latest updates on Dechra Pharmaceuticals from Fool.com.
3 FTSE Shares Hitting New Highs

LONDON -- The FTSE 100 (INDEX: ^FTSE) is edging ever closer to its 52-week high of 5,989 points...



Stock Performance

View Interactive DPH Charts
Sponsored by

Key Data Points

Primary metrics and data points about Dechra Pharmaceuticals.
Current Price: $1,249.62
Prev Close: $1,272.00
Open: $1,264.00
Bid: $0.00
Ask: $1,500.00
Day's Range: $1,243.00 - $1,273.47
52wk Range: $811.00 - $1,462.00
Volume: 190,451
Avg Vol 160,403
Market Cap: $116B
P/E (ttm): 0.00
EPS (ttm): $0.00
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Dechra Pharmaceuticals.
CAPS Rating 0 out of 5
 
0 Outperform
0 Underperform
CAPS All Stars
 
0 Outperform
0 Underperform

How do you think Dechra Pharmaceuticals will perform against the market?



You pick for Dechra Pharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mike Redmond, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Dechra Pharmaceuticals.

Dechra Pharmaceuticals, founded in 1997 following a management buy-out from Lloyds Chemists, develops prescription only veterinary medicines for dogs, cats and horses. Most of its projects involve adapting treatments, currently used by humans, for the animal market. It listed in London in 2000.

  • Exchange: LSE